Pure Global AI
NCT06345287Recruiting

Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related HNSCC

Response Adaptive Radiotherapy Following Immunotherapy-based Induction for Non-HPV Related Head and Neck Squamous Cell Carcinoma
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2ClinicalTrials.govradiation
Verified
Study focus
Disease/Condition
Head and Neck Cancer
Drug/Device/Intervention
radical radiotherapy (60Gy)
Study type
Interventional
Intervention type
radiation
Sponsor & location
Primary sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Location
Beijing, China
Timeline & enrollment
Phase
Phase 2
Start date
Jan 01, 2024
End date
Dec 31, 2026
Enrollment
133 participants
Primary outcome

Progression-free survival

Summary

The aim of this study is to develop an adaptive radiation therapy plan for locally advanced
 head and neck squamous cell carcinoma receiving induction therapy containing immunotherapy
 and chemotherapy. The therapy plan is based on clinical remission, in order to reduce
 treatment-related toxic side effects without sacrificing clinical efficacy and improve the
 quality of life of patients.

ICD-10 classifications
Malignant neoplasm of other and ill-defined sites: Head, face and neckMalignant neoplasm: Skin of scalp and neckMalignant neoplasm: Connective and soft tissue of head, face and neckCarcinoma in situ: Skin of scalp and neckSecondary and unspecified malignant neoplasm: Lymph nodes of head, face and neck
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06345287
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06345287 through Pure Global AI's free database. This Phase 2 trial is sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences and is currently Recruiting. The study focuses on Head and Neck Cancer. Target enrollment is 133 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.